TY  - GEN
AU  - Lozano, Rebeca
AU  - Jayaram, Anuradha
AU  - López-Campos, Fernando
AU  - Saez, Maria I
AU  - Montesa, Alvaro
AU  - Gutierrez-Pecharoman, Ana
AU  - Villatoro, Rosa
AU  - Herrera, Bernardo
AU  - Correa, Raquel
AU  - Rosero, Adriana
AU  - Pacheco, María I
AU  - Garcés, Teresa
AU  - Cendón, Ylenia
AU  - Nombela, Ma Paz
AU  - Van de Poll, Floortje
AU  - Grau, Gala
AU  - Rivera, Leticia
AU  - López, Pedro P
AU  - Cruz, Juan-Jesús
AU  - Lorente, David
AU  - Attard, Gerhardt
AU  - Castro, Elena
AU  - Olmos, David
PY  - 2018
DO  - 10.1038/s41416-018-0123-9
UR  - http://hdl.handle.net/20.500.12105/17619
AB  - Despite most metastatic castration-resistant prostate cancer (mCRPC) patients benefit from abiraterone acetate plus prednisone 5 mg bid (AA + P), resistance eventually occurs. Long-term use of prednisone has been suggested as one of the mechanisms...
LA  - eng
KW  - Aged
TI  - Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
TY  - research article
ER  -